Trial Profile
A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Romosozumab (Primary) ; Romosozumab (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Amgen
- 06 Feb 2010 New trial record